Dermatology

Why GLP-1 Matters Here

GLP-1's anti-inflammatory mechanism operates through inhibition of IL-17, TNF-alpha, and IL-6, cytokines directly involved in the inflammatory cascades underlying psoriasis, hidradenitis suppurativa, and other inflammatory skin conditions. The receptor distribution extends to keratinocytes and dermal fibroblasts, which means GLP-1 agonism affects skin physiology through both systemic anti-inflammatory effects and direct receptor-mediated action on skin cells.

Clinical documentation includes a 73-year-old patient with severe psoriasis refractory to adalimumab who experienced a 92.2 percent reduction in PASI score on semaglutide, a 31-year-old woman with Hurley Stage II hidradenitis suppurativa whose severity dropped from severe to minimal on liraglutide, and a patient with Hailey-Hailey disease who experienced significant improvement through GLP-1-mediated IL-17 reduction. A 2025 McKinsey survey of aesthetics providers found that 63 percent of patients seeking facial treatments related to GLP-1 use had never been active consumers of medical aesthetics before.

Two distinct GLP-1 mechanisms are driving additive demand into dermatology practices simultaneously: inflammatory skin condition patients whose conditions are resolving on GLP-1 therapy, and a body contouring and facial restoration cohort driven by rapid weight loss. Both cohorts represent patients who did not previously present at this scale.

What the Data Shows

This vertical has no government fundamentals source. Research citations represent published findings from named organizations using specific methodologies. Search interest reflects consumer information-seeking behavior via Google, which may understate real interest as users migrate to AI search tools.

Analysis

The psoriasis biologic market is substantial. Adalimumab and its biosimilars, secukinumab, ixekizumab, and other IL-17 inhibitors generate significant revenue per patient per year. Case reports of psoriasis remission on semaglutide in patients refractory to these biologics are clinically significant precisely because they represent treatment-resistant cases resolving on a drug not prescribed for dermatological indications.

The aesthetic demand side is equally significant and more immediately measurable. A 63 percent new-patient rate in aesthetic dermatology practices represents additive demand, not cannibalization of existing patient volume. Practices that develop protocols for GLP-1-related aesthetic presentation are capturing a growing patient cohort with no established referral pattern competing for them.